---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-002947"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:10:36.814614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zomedica reports 2022 revenue of $18.9M, up 361% YoY; net loss narrows to $17.0M

## Summary
- Revenue $18.9M, up 361% from $4.1M in 2021; 72% gross margin.
- Net loss $17.0M vs $18.4M in 2021; improvement of $1.4M (8%).
- Cash, equivalents and securities $156M at Dec 31, 2022; no SVB/Signature exposure.
- PulseVet small-animal device sales grew 405% in 2022; VetGuardian launched; TRUVIEW expected Q2 2023.
- Acquisitions of Assisi and Revo Squared contributed; evaluating further M&A.

## SEC filing metadata
- accession: 0001654954-23-002947
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495423002947/0001654954-23-002947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495423002947/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-002947
- JSON: https://secwatch.observer/filing/0001654954-23-002947.json
- Plain text: https://secwatch.observer/filing/0001654954-23-002947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.